Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × nilotinib × Sarcoma × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4 Sarcoma 1 Gynecologic 1

Conditions

Gastrointestinal Stromal Tumors 14 Neoplasms 3 Sarcoma 1 Retroperitoneal liposarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Piebaldism 1 Neoplasm Metastasis 1 Liposarcoma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leiomyosarcoma 1 Gastrointestinal Neoplasms 1 Disease Progression 1 Chondrosarcoma 1

Interventions

pembrolizumab 8 Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 8 Cyclophosphamide 8 Specimen Handling 7 pazopanib 6 Biopsy 6 Radiosurgery 5 Nivolumab 5 Magnetic Resonance Spectroscopy 5 Imatinib Mesylate 5 Bevacizumab 5 regorafenib 4 Zoledronic Acid 4 Irinotecan 4 Docetaxel 4 Radiation 3 Ifosfamide 3 Cryosurgery 3 Carboplatin 3 trastuzumab deruxtecan 2 trametinib 2 temsirolimus 2 sargramostim 2 olaparib 2 masitinib 2 ganitumab 2 futibatinib 2 conatumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡